Physician profile
Jean M Paul
NPI 1932102639
$1,100.62
in general payments reported to CMS, 2019-2025
12 companies · $22.28 in 2025
The $22.28 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $33.50 · 2021: $54.09 · 2022: $418 · 2023: $241 · 2024: $207 · 2025: $22.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $470.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $469.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $381.49 | 2019-2024 | Ofev, Jardiance |
| Abbvie INC. | $210.61 | 2021-2024 | |
| Novo Nordisk INC | $138.41 | 2021-2023 | Wegovy |
| Harmony Biosciences LLC | $124.98 | 2022 | |
| Abbott Laboratories | $48.89 | 2022-2023 | Freestyle Libre 3 |
| Amgen INC. | $46.68 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.44 | 2024 | Xifaxan, Trulance |
| Allergan, INC. | $33.50 | 2020 | |
| Lilly USA, LLC | $29.87 | 2023-2024 | Jardiance, Emgality, Mounjaro |
| Seqirus USA INC | $22.28 | 2025 | Fluad, Flucelvax |
| Takeda Pharmaceuticals U.S.A., INC. | $12.81 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $11.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jean Paul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.